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Investigators are using health-related quality of life measures 
more and more in controlled clinical trials, including trials in 
patients with heart faihue. The purpose of this report is to 
provide abasic introduction tothe measurement properties 
necessary for adequate measurement of health-related qual- 
ity of life and the available approaches for such measure- 
ment and to introduce xamples of health-related quality of 
life measurement i  patients with heart failure. This review 
is not intended as a detailed update on the health-related 
quality of life studies. The interested reader will find more 
extensive r views (1-3) available lsewhere. 
What Is Health-Rehted Qdty of Life? 
Health status, functional status and quality of life are 
three concepts often used intercmy to refer to the 
same domain of “health.” The health domain ranges from 
negatively valued aspects of life, including death, to more 
positively valued aspects such as role function or happiness. 
The boundaries ofdefinition usually depend on why one is 
assessing health and the particular concerns of patients, 
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clinicians and researchers. I use the term “health-related 
quality of life” because many widely valued aspects of life 
are not generally considered as“health-&ted,” including 
income, freedom and quality of the environmen t. AMlough 
low or unstable income, htck of freedom or a low quality 
environment may adversely a&t health, these problems are 
often distant from a health or medical concern. For clink 
chns. health-related quality of life is the appropriate focus, 
keepinginmindthatwhendiiandiUnessareexperi- 
encedbyapatient.ahnostaUaspectsoflifecanbecome 
health related. 
Key Measurem ent Properties 
Understanding ofthe use of health-&ted quality of life 
measures in cliical trials requires famiKty with three key 
measurement properties of these instnmmnts. ReliaMify 
refers to the ability of an instrument toconsistently disuim- 
inate between subjects, and it is important when one is tryhtg 
to determine the decrement in a patient’s health-&ted 
quality of life in relation to that of other patients (4). 
Responsiwerress fers to an instnunent’s abii to detect 
change. Ifa Weatment results in an important diabrence in
health-related quality of life, investigators want o be conti- 
dent they will detect hat difference, ven if it is smal!. 
Responsiveness will be directly related to the stability of 
scores in patients whose condition has not changed and to 
themag&udeoftheiWerenceinscoreinpatientswhase 
condition has improved or deteriorati that is, the greater 
theratioofthechangeinsc~insuljectswith~important 
073540!37/W%.~ 
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. mqmwem&ordetu&&oninhe&h-relatedquatityoflife 
titouglity in stable subjects, the greats% ths respon- . . 
m 0-n 
validity, the thild key property, refers to whether an 
. msuumentismeasuringwhatitissupposedtomeasure,aud 
itisdwmmshatedbyshowingthatchangesintheMrument 
~hw&i@edcolTehltewith~inotherrelated 
measuresinthethwmtMydelived~dhectumand 
maguitude(8,9).Theprucessddev&phtgthetheorythat 
permitsthesepmdictionsinvolves~exactlywhatone 
is trying to measure (the target construct-for example, the 
SbiliQtO-activitieSOf~~liVillg)dconaidering 
ther&tionthatshouldexistbetweenthetar@construct 
and other wn&ucts (for example, Momtory exercise ca- 
pacity). This involves demonsttatinq not only modemte 
colT&ionswithinstrumentsdhectedatsimihirconsttucts, 
butalsolowerorabsentcorrelationswithinsuumentsdi- 
tected at di&rent constructs. 
Hsdthpra8kr.Twobasicappmachestomeas~ 
health-related quality of life are available (10). Generic 
. ~applytoawidevarietyofpatients.Theirbroad 
applicsbilityisingenelalderivedfrolutheircovemgeofthl? 
completespecttumoffktion,disabihtyanddistmssthatis 
relevanttollealth+elatedqualityoflitb.Thetearehvomaior 
classes: health pro&s andtuility meaawes. 
Healthpm&SamsiqBLe~thatmeasllrediuhmnt 
sspsctsofhsake&dqualityoflikHealthpxehleushsrea 
amuwnacoriqBsystemandcaube~intoasmfdl 
numherofsanesandsom&nesintoasinglescom.Asgmuic 
measures,th9atedes@lfcrusehtawidevwietyof 
conditkas.F~eXample,~dtbcmogCpupuhuhetdth 
proke&esicknessImpactRofilecomains12~that 
caubs~intotwodansinsaud6veindependenc 
aIk#u&u&wellvell ““~C scorn (11). Another 
as part ofths I&dicGscs study (123). 
Healthpro6lesoks9eraladvantages.Theyallow . . 
~cftheefkctsoftheh&9entionondikent 
aspsctsofhealth-relatedqualityoflif&withouttheuseof 
multiple in&uments. &cause th9 are desiied for a 
WidCvarietyOfCOnditiOllS,OaeCSllcomprrnthC~CCtSOll 
health-related quality of life of interventions i  diKerent 
diseases. 
Healthpro6lesalsohavelimMons. Theymaynotfocus 
on the aspects of health-&ted quality of life of specific 
~-sttothGltinve~tor.InedequatefibcusWtheqtt$dity 
of hk issues of a speck t&l is likely to result in an 
~9onsiveinstrumentthatmaymisssmaubutstiucliai- 
Cauy @oHant changes in health-refated quality of life. 
UMltJtw-mmtu. Theotherapproa&togenericmea- 
=ementistheuseofutilitymeasuresdhealth-related 
tpdityofli&thatarederivedfmmewnomicanddecision 
theoryandn&ctthe~ncesofpatientsfortreatment 
process and outcome. Health-related quality of life is mea- 
sured as a single number along acontinuum from death (0.0) 
to tilll health (1.0) (14). 
Therearutwofundamentalapproa&estoutilitymeasure 
lllCUtiUClillidtlialS.One,~OIlwhatiScalleddti- 
attriilltility~,istoaSk~questioasabout 
the!irfilllction.ontllebaSiSdtlleir~,~SrC 
classi6edhttooneofseveralcat9ork.Bachcategoryhasa 
utilityvalueassociatedwithit,theutilityha~been 
establishedinpreviousratiugsbyanothergroup(suchasa 
random sample of the general population). The most widely 
used&tnunemthattakesthisapproachistheQualityof 
well Ekii instrument (1% 
Thesecondapprcachistoaskpatkntstomakeasingle 
ra in2thattakesintoaccountallaspectsoftheirhtxdth- 
relatedquslitydlife.There~manywaysthisratingcanbe 
made. The standard gamble asks ubjects tochoose between 
thejrownhealthstateanda~bleinwhichtheymaydie 
. mmMatelyorachievefuUhealthfortheremaiudtwoftheir 
lives. Usinq the sta&ni gamble, utility or health-related 
quality of life is determined by the choices they make as the 
probabilitiesofimmedMedeathorfullhealtharealtered.In 
a simplifted and more widely used technique, std#cts are 
asked about the number of years in their present health state 
th9wouldbewiUinqtotmdefmashorterlifespsninftdl 
health. 
Utilitymeasuteshavethem&radvau~ofame&ility 
to cost-utility analysis. In cost-utility analysis, the cost of an 
httervention s related to the number of quality&justed 
lifeyears (QUALYs) gahttsd through application f the in- 
tervention. For instance, using the Quality of Well-Being 
scale, Toevs et al. (16) showed that a ptogram des@ed to 
huprwvecom@aucewithauexetciseprograminchronic 
aitflowlim&ioncouldimprovehealth-relatedqualityof 
life. The costatility analysis showed that the cost of the 
plogramwas224256foreachadditionalyearofwellbeinq 
(or QUALY) qained (16). The costutility of ditknt inter- 
ventionscanthenbecompared.MentiaUy,thish&mnaGon 
cauhelppokymkmchoosetheoptimalauocatiouof 
scarcelesource8. 
utility-alsohaslimitations.utilitymea- 
s r ments am vary dependiqt cm how they are obtained, 
raisiiquestionsofthevalidityofauysinglemeasurement. 
ThlEydonotalhNHheiwestigatmtodetermiuewbat~pects 
ofhealth-mlatedqualityofli&aterespmGbleforchangesin 
utility. Finally, they may sham the disadvantage of health 
profksinthattheymaynotberesponsivetosmallbut 
clinkauyimportantchanges. 
Specific Measures 
Analtemativeapprwchto~~qualityoflife 
~tistotbcusonasuectsofhealthstutusthatam 
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approach lies in its potential for increased responsiveness, 
which may result from including only important aspects of 
health-related quality of life that are relevant to the patients 
being studied. The instrument may be specific to the disease 
(instruments for chronic lung disease [17] or asthma [If!]), 
specific to a population of patients (instruments designed to 
measure the health-related quality of life of the elderly, who 
may be a&ted with a wide variety of ditferent diseases, 
specific to a certain function (questionnaires that examine 
emotional or sexual function) or specific to a given condition 
or problem (such as pain) that may be caused by a variety of 
underlying pathologic conditions. 
Claims about health-related quality of Me may be based 
on questionnaires with diverse content. Investigators need 
to review in detail the content of questionnaires they are 
considering using to ensure that he areas they wish to target 
are covered. This highlights an advantage of many specific 
measures that relate closely to areas routinely explored by 
the physician. The disadvantages of specific measures are 
that hey are (deliberately) not comprehensive and cannot be 
used to compare across conditions. They are designed to 
focus on elements specific to a target condition and therefore 
do not measure drug toxicity and certainly will not detect 
unforseen side effects unrelated to manifestations of the 
target condition. They are also less likely than generic 
measures tohave carefully considered the relative values of 
individual questions or domains within the questionnaire, 
and the typical approach isto weight items equally. 
Specific instruments for heart failure have been used in 
several randomized trials and represent the approach tohealth- 
related quality of life measurement in heart failure that has to 
date been most frequently applied. The remainder of this 
review wiil provide examples of ho* speci% health-relatuzd 
quality of life measures have been used in clinical trials in heart 
failure. Before moving to these examples, however, 1will 
briefly discuss issues of questionnaire administration. 
Questionnaire Administration 
The history of heaith-related quality of life measurement 
in clinical trials is strewn with failures caused by inadequate 
attention to compliance and administration. The principles 
of use of questionnaires to ensure optimal performance 
include the following. 
1. Recognition ofhnportauce. If investigators t eat ques- 
tionnaires as minor additions to a protocol, they can be 
assured that compliance will be poor and missing and 
inaccurate data common. Health-related quality of life ques- 
tionnaire administration must have the same priority as, for 
instance, measurement of hypertension within a trial exam- 
ining medication to lower blood pressure. 
2. Training Inte&ewers. Interviewers, orthose supervis- 
ing self-administered instruments, must be properly trained. 
Important principles include rigid adherence tomodes and 
wordii of instructions and avoiding bias in administration 
that may arise through explanations that suggest that some 
responses are more appropriate han others and through 
verbal and nonverbal expressions of approval or disap 
proval. 
3. MonitAng. Even after adequate raining, interviewers 
can easily go astray. Trials must include monitoring mecha- 
nisms to ensure adherence toprinciples of questionnaire ad- 
ministration. 
Disease-Specific Measures in Heart Failure 
The Chronic Heart Failure Questionnaire. I wiIl use the 
example of our own instrument to illustrate how diiease- 
specific measures can be developed and tested in the setting 
of controlled clinical trials. We began by constructing a list 
of items likely to be important to patients with heart fa&e 
(19). The items were generated through a review of pub 
lished reports, consultation with cardiac nurse specialists 
and cardiologists and unstructured interviews with patients. 
The final Item Selection Questionnaire contained I23 items, 
of which 61 dealt primarily with physical function and 62 
with emotional or social function. This questionnaire was 
administered to 88 patients with a clinical diagnosis cfheart 
failure supported by echocardiographic, angiographic or
radionuclide angiographic evidence of cardiac dysfunction. 
The patients were asked if the 123 items represented ways in 
which their lives were affected by their heart problem. 
Patients rated the importance ofeach atlirmatively answered 
item on a 5-point scale. We chose the items that were most 
frequentiy labeled as problems and were most important for 
the final Chronic IIeart Failure Questionnaire. The items feU 
into three domains: dyspnea, fatigue and emotional function. 
In the dyspnea domain, we found that the items chosen 
varied widely depending on the patient’s gender, range of 
activities and level of disability. In the Chronic Heart Failure 
Questionnaire, therefore, we ask patients to choose the five 
activities associated with shortness of breath that they do 
frequently and are most important intheir daily lives. Over 
the course of a study, we repeatedly ask patients the extent 
of their dyspnea in those five activities. Items on each of the 
three domains are presented as 7-point scales. 
Studies (20) of Chronic Heart Failure Questionnaire mea- 
surement properties took place within a study of digoxin in 
patients with heart failure. Patients in sinus rhythm with 
echocardiographic evidence of left ventricular dysfunction 
and significant functional disability participated in a double- 
blind randomized trial in which they were then given digoxin 
and an identical placebo, each for 7 weeks, the order 
determined by random allocation. Visits were planned for 
the end of weeks 3,s and 7 of each treatment period, but if 
a patient’s condition deteriorated, the period was terminated 
prematurely and outcome measures were obtained. Mea- 
sures of outcome included a clinica! heart failure score 
(including findings from history, physical examination a d 
chest radiograph) (21), a 6-mitt walk test @2), the Chronic 
Heart Failure Questionnaire, global ratings of change in 
dyspnea, Mgue and emotional function, the Specific Activ- 
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scomnoCoatrontdTrialof~xin 
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21.2 19.5 0.044 
mm la4 16.1 0.37 
Elwhlllm 37.3 36.2 0.09 
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ity Scale (23) and New York Heart Ass~cjation functional 
CiUilhthll. 
The study showed digoxin to be of benefit. Seven patients 
required a shortened study period because of increas@ 
hesrt fhilure; ail seven treatment failures occurred while 
patients were takii piacebo (p= 0.016). The Chronic Heart 
Failure Questionnaire showed trends favoring digoxin that 
were found in all three domains (Table 1). However, the 
digoxin-imluced banqes indyspnea were small, and the 
changes in Mque and emotional function were very small. 
Qnly for the dyspnea domain did the dil%erence between 
digoxin and placebo reach conventional levels of stutisticai 
si@ftcance. 
The resuits suguest two possible conclusions. 1) Digoxin 
didnotmakeanydiiferenceinfatiqueandemotionalfunc- 
tion (and only a small dikence in dyspnea), or 2) diiuin 
hadanimpormnteifectthattheChronicHeartFailure 
Question&e Med to detect. To elucidate his issue, we 
examined changes in scores insubjects whose giobai raw 
ofchange sugqested improvement or deterioration between 
study visits, kespeck of the treatment they were teceiv- 
ing. If the Chronic Heart Faiiure Questionnaire is respon- 
sive, one would anticipate animprovement in score that 
would be statisticaily &u&ant. For example, 11 of the 20 
subjects reported au improvement in their giobai rat& of 
dyspnea atsome time during the study (Table 2). Scores in 
the Chronic Heart Fake Questionnaire dyspnea domain 
imptwed over these visits, and a paimd t test showed the 
d&rences to be statisticaily !&n&ant (Tabie 2). The Snd- 
ings & each of the three domains were simiiar, despite he 
smsilnumberofsubjectswhorepoltedanimpnwement(pRr- 
ticuMyinemo&uslknction)atsometimeduringthestudy. 
Theseresuitssug2estthattheChronicHeartFaiiureQuesGou 
ttsimislv!sponsivetoimprovementinkaithstatus.Ibc 
llnd@sinsu&ctsw~cond&mdeMuakdaisoshow 
substantial~ncesthatarestatistically~t~~~2). 
Because there is no reference standard for health-related 
qualityofiik,itisachakngetodetermkwhethera 
questionnaire reaiiy measures health-related quality of iifk 
One uses an approach caiied “construct validity.” If an 
instrument is valid, changes in score should relate to changes 
in other measures in a prudktable fashion. We made the 
foliowinq predictions about how the Chronic Heart Faiiure 
Questionnaire should behave ifit is reaiiy measuring heaith- 
related quaiity of life. The predictions are followed by the 
results actually observed: 
1. Change inthe three Chronic Heart Faiiure Question- 
naire domains should bear a close relation (r 2 0.5) to 
changes in a patient’s corresponding giobai ratings of 
change. Tbe correlation between change indyspnea score on 
the Chronic Heart Failure Questionnaire and the global 
rating of change indyspnea was 0.65 (p c O.OOl), between 
chaage infatigue scotu on the questionnaire and the giobai 
r ting of change in fat& was 0.62 @ c O.OOi) and between 
chanqe in emotional function score on the questionnaire nd
th  giobal rating of change inemotional function was 0.34 
@ < 0.001). 
2. Change inChronic Heart Faiiurc Questionnaitc dys- 
pnea score should relate closely (r2 0.5) to change inwaik 
test score. The correlation bserved was 0.60. 
3. Change inChronic Heart Fake Questionnaire dys- 
pnea score should bear a moderak correlation (r > 0.4) with 
change inheart failure score. The correlation bserved was 
0.42. 
The strong coneiations support the validity of the ques- 
tionnaire. Additionai support isprovided by the gradient of
conelation: sttwnger correlations for measures more closely 
tied to functionai capacity, a weaker correlation with the 
heart ihike score, which rellects he ciinician’s a sessment. 
It wouid be worthwhiie lulowing how other functional 
status measures used in patients with heart failure compare 
with the Chumic Heart Failure Questionnaire. B cause the 
New Yotit Heart Associatk and Specik Activity Scale 
provide measures ofdyspuea during daily activity inpatients 
withheart&ilute,the~comparisoniswiththe 
Chronic Heart Failure Questionnaire dyspnea score, and if 
these other instruments arevalid, then predictions mgardii 
Chronic Heart Failure Question&e dyspnea score should 
also apply. Correlations between changes in Chronic Heart 
Failme Questionnaire dyspnea score, the New York Heart 
AssociatioufimctionalciassandtheSpeciiActivityScale 
ontheonehand,aodglobelratingofc~indyspnea, 
chatqgeinwalktestscoreandchangeinheartfaiiutcscomon 
the other, are shown in Table 3. ‘Ilte cor&&ms are 
consistentlyh@erwiththeChrouicHeartFailureQuestion- 
nairedyspneasuuethanwiththeotherktruments,s~ 
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Table3. Correlations Between Cbmic Heart Failure 
Questioanaire (CHQ) Dyspnea Dimension, New York Heart 
Association (NYHA) Fuuctioual Classification and Specific 
Activity Scale @AS) Classificrrtion 
Global RaIii 
of- in Change in cllangcin 
shortnersof Walk Test Heart Failure 
Breeth 
CHQdyqmeascorc 0.65 0.60 0.42 
NYHAlhtid 0.20 0.24 0.10 
Ldnsdicatiw 
SAscla!dcatiw 0.34 0.11 0.04 
Innaturaltmits,-bctwcmNewYorkHeartAssociation 
thtionalclassandtheSpecikActivityScaleaudothermcasmesare 
n~&ve;the&nbasbeenreversalfbamparisonpuposes. AUcodatiis 
Ml.20 are statistically sign&ant at the 0.05 level. 
gesting that he former is a more valid measure ofchanges in
shortness of breath in patients with heart failure. 
Other speelile hMrumentx Ru heart fallure. The Chronic 
Heart Failure Questionnaire s not the only disease-specific 
health-related quality of ltie measure that has been used in 
clinical trials in heart failure. Blackwood et al. (24) used 
visual analog scales that addressed areas of breathlessness, 
anxiety, depression, irritability, tiredness, energy, concen- 
tration, sleep and limitation of activities ina controlled trial 
of xamoterol and digoxin in heart failure. The trial failed to 
show differences between the treatments and placebo in 
either measured exercise capacity or health-related quality 
of life, although both measures improved in all groups. 
Siiant associations between changes inexercise capac- 
ity and changes intotal score on the visual analog scales and 
breathlessness were demonstrated, but the magnitude of the 
correllons were small. 
Tandon et al. exam&l the performance of a !Mem 
disease-specilic Self&ting Scale and thtt generic measures 
(the QL Index [26], the Sickness Impact profile [n] and the 
Quality of Well-Being [In in a mndomixed trial in which 
patients received “standard therapy’* or “placebo replace- 
ment for standard therapy.” The SelfMng Scale and the 
QL Index were able to di&retuiate the two conditions, 
whereas the other two instruments were not, suggesting that 
the former two instruments may be more responsive than the 
latter two. 
l&e Minnesota Living with Heart Fake Questionnaire. 
Ikdoped by Rector et al. (28), this instrument consists of 
21 items focused on patient perceptions concerning the 
elfects of congestive h art faihue on their physical, psycho- 
logic and socioeconomic lives. Response options are pre- 
sented as O-point scales. In initial testing, these investigators 
found that he instrument is reproducible (weighted kaw on 
readmhdstration at 7 to 21 days 0.84). In addition, they 
obtained initial evidence of validity (con&&n with global 
ratisg O.&u and with the New York Heatt Association 
fun&maI class 0.60). 
They used the Sickness Impact Mile and their specific 
questionnaire n a before and after study of an experimental 
inotrope. Despite lack ofchange in arterial pressure, pllmo- 
nary wedge pressure, cardiac index or exercise capacity, 
patient scores on both questionnaires improved and the 
diierence reached conventional levels of statistical sign& 
cance. The design could not show whether these changes 
had anything to do with the experimental intervention (29). 
The Minnesota Living with Heart Failure m 
performed in a very impressive fashion in a dot&-bIind, 
mndomb!ed,nudticentertrialofpimobendaninpatientswith 
moderate osevere heart failure. Patients were randomized 
to receive ither placebo r three different doses ofpimobcu 
dan (2.5, 5 and IO mg). Approximately 5O patients were 
randomized to each of the four treatment regimens. The 
questionnaire was self-administered under supervision. 
Trends in favor of active drug versus placebo in both 
exercise capacity and health-&ted quality of life were seen 
for all three doses, but the largest differences were seen with 
the S-mg dose. The statistical power of the exercise t st and 
the questionnaire w re comparabb (pvalue assochued with 
cws in the 5-mg roup vs. placebo group were c 0.01 for 
both measures) (30). 
The invest&tot-s also examined the validity of the ques- 
tionnaire inthe context of the trial. Changes inquestionnaire 
scote were not related to changes in ejection fraction. 
However, changes intotal score and physical fimctkm score 
(but not emotional fit&ion) showed weak to moderate 
correlations with changes in exercise time (0.33 and 0.35, 
respectively). The questionnaire was able to disti@sh 
patients whose global ratings of dyspnea nd fatigue showed 
improvement or de&oration from those who mported no 
change (31). The overall pattern of wrreUms (higher 
correlations for variables more closely related to quality of 
life, lower correlations for ejection traction) supports the 
validityofthequestionnaire. 
Further evidence for the responsiveness ofthe question- 
naire comes from the Studies of I.& Ventricular Dy&mc- 
tion (SQLVD) Trial (32). Data ti 37 patients with overt 
heart&ihtrewhoreceivedenak@land4OsuchpaGentswho 
received placebo were available. Both the physical fun&m 
dimensionandthetotalscore(butnottheenMkmalfunction 
dimension) showed improvements relative to placebo @ C 
0.001 and c 0.01, respectively) (32). 
Taken together, these results provide sbon# evidence 
thattheMinnesotaLivingwithHeartFaihueQuestioanaire 
is responsive tothe sort of changes inhealth-related quality 
of life that follow from the administration f eifective med- 
ication. The question&e has the advantage of being self- 
administered.Furtherdataconcemingvahdityd~~ 
tionnaire would he desirable. Determhmtion fthe changes 
thatconstitutesmall,mediumandlargeeffectswould~~ 
helpful. Nevertheless, the data available to date are very 
enco=S& 
Tire We de. One other hstrumwt has demOaSm4 
~sponsiveness in the context of ttltdticemer m&Jmi%d 
t&& the Yale scale. This instrument examines patients’ 
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dyspneaandfetieuebyaesregating~~:~e 
specikphysicaltaskthatcausesdyspneaandht@e,the 
&lt~plCeWithWhiClltbet?lSkiS~CUlddlS 
petieat’s gen#al tilnchd tapcity (33). The instrument 
providcsguideshrquestionsaskedbyheaUperso=l 
&erthaaaspeci6cseqaenceofquestkms.Theinstnunent 
pF@vedruqxmsiveiatwo~cliniceltlials,demon- 
strat&greaterimprovementwithMnoprilthanwithcap 
toprhrplacebo.rn~tlleitlvestigatorsfinlndmod- 
eaateCoI&tioasOfChaDgeilltheYaleSGde~~Sia 
&balratingsofdyspnsaandf&igaeandezenkecapacky. 
ThGSCfiadiags~ipqpreSSi~alldS~thSttllSscale 
couldbeveryusefidiadekmkhg~e&tsondyspne!a 
audfatigle.Itdossnot,however,addmsothefanasd 
hcaltll&ated quality of life. 
Q&i@ qfL#k Que&nnai~ in Severe Heart Faih. 
Wiklundetal.(34)usedamethodologyquitesimilartoour 
owatodeveloptbeirQuaiityofLihQuesh&einSeven 
HeartFailue.A!JlMemqaestionoahwasadmihteredto 
51patkatswitbllcaIt&rilure.~-six~~chosen 
fiopthe6nalqaestiannshonthelmsisoftheaumbcrof 
patkntswhohhti6edtheitemasasinnificantproblem,the 
extenttowldchacardh&tthoughttheywere@xntaat 
problemsaaddexnoastratedhi&hctorloul&ontheap- 
~_~p~*~~The~qaestioa- . 
-II alld phys- 
ical limit&m d&Mills. The test-retest rehbihy of the 
-a&r 1 weekwaso.75too.85. valklitywasdemon 
stlatedby-ofo~too.72with~~ 
ofthesicba!M~~,theMoodArljectivecheckList 
andacardh&fa~ofthepatienS’s~ 
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